Sanus provides new sources of data to assist pharmaceutical companies in research and development of new treatments and drugs. We address three major challenges faced by pharmaceutical companies.

First, we facilitate recruitment and retention of patients and hospitals that together account for 56% of clinical trial costs. We can save companies time and money by expediting recruitment for clinical trials and ensuring the required enrollment is met. Our broad base of affiliates and incentives provide a sustainable source of patients and sites for multi-center and decentralized clinical trials.

Second, we provide data for Virtual Drug Screening (VDS) services. This data allows pharmaceutical analysis of drugs by their signature behavior in a myriad of test systems, including different cell lines treated with a variety of drugs with any similarity to the therapeutic being developed. The VDS approach powered by clinical data with Real World Evidence (RWE) of many patients can provide approximately 80% of the information of some preclinical and early clinical work for about 5% of the time and effort. Of course testing of the new drug empirically is essential to understand risks and prove efficacy (including for regulatory approval), however, VDS connected to Real World Evidence (RWE) from clinical response to related drugs with a similar mechanism of action, can greatly reduce the amount of physical testing, replacing it with digital “testing” (VDS analysis).

Third, we facilitate submission of documents to the regulators, such as 510(k) or NDA filings. Our secure cloud-based platform is well suited to provide consistent analytics and presentation with which the regulators become familiar. The cloud portal also allows selective release of some data to the FDA during the pre-submission process. This communication is important to build rapport with the regulatory agency in question, to expedite and facilitate the filing process.